Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor

Patent metadata

Field	Value
Publication number	US-2016032012-A1
Application number	US-201414775108-A
Country	US
Kind code	A1
Filing date	Mar 14, 2014
Priority date	Mar 15, 2013
Publication date	Feb 4, 2016
Grant date	—

Abstract

The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPIα, even where the concentration of TFPI is abnormally elevated.

First claim

1 . A bispecific antibody that is capable of specifically binding tissue factor pathway inhibitor (TFPI).

2 . The bispecific antibody according to claim 1 that is capable of specifically binding a first epitope of tissue factor pathway inhibitor (TFPI) and a second epitope of TFPI, wherein the first epitope comprises an amino acid residue located within positions 1 to 181 of SEQ ID NO: 1 and the second epitope comprises an amino acid residue located within TFPI positions 182 to 276 of SEQ ID NO: 1.

3 . The bispecific antibody according to claim 1 , wherein a first epitope comprises an amino acid residue within the KPI-1 domain of tissue factor pathway inhibitor (TFPI).

4 . The bispecific antibody according to claim 1 , wherein a first epitope comprises an amino acid residue within the KPI-2 domain of tissue factor pathway inhibitor (TFPI).

5 . The bispecific antibody according to claim 1 , wherein a second epitope comprises an amino acid residue within the KPI-3 domain of tissue factor pathway inhibitor (TFPI).

6 . The bispecific antibody according to claim 1 that is capable of specifically binding tissue factor pathway inhibitor (TFPI), wherein said antibody is capable of binding a KPI-1 epitope comprising one or more amino acid residues selected from the group consisting of Leu 16, Pro 17, Leu 19, Lys 20, Leu 21, Met 22, Phe 25, Cys 35, Ala 37, Met 39, Arg 41, Tyr 56, Gly 57, Gly 58, Cys 59, Glu 60, Gly 61, Asn 62, Gln 63, Arg 65, Phe 66, Glu 67, Glu 71 and Met 75 of SEQ ID NO: 1.

7 . The bispecific antibody according to claim 6 , wherein said antibody is capable of binding a KPI-1 epitope comprising amino acid residues Arg 41, Arg 65 and/or Glu 67 of SEQ ID NO: 1.

8 . The bispecific antibody according to claim 1 that is capable of specifically binding tissue factor pathway inhibitor (TFPI), wherein said antibody is capable of binding a KPI-2 epitope comprising one or more amino acid residues selected from the group consisting of Glu 100, Glu 101, Asp 102, Pro 103, Arg 107, Tyr 109, Thr 111, Tyr 113, Phe 114, Asn 116, Gln 118, Gln 121, Cys 122, Glu 123, Arg 124, Phe 125, Lys 126 and Leu 140 of SEQ ID NO: 1.

9 . The bispecific antibody according to claim 8 that is capable of specifically binding tissue factor pathway inhibitor (TFPI) wherein said antibody is capable of specifically binding a KPI-2 epitope comprising amino acid residue Arg 107 of SEQ ID NO: 1.

10 . The bispecific antibody according to claim 1 that is capable of specifically binding tissue factor pathway inhibitor (TFPI), wherein said antibody is capable of binding a KPI-3 epitope comprising one or more amino acid residues selected from the group consisting of Tyr 207, Asn 208, Ser 209, Val 210, Ile 211, Gly 212, Lys 213, Arg 215, Lys 232, Gln 233, Leu 236 and Lys 240 of SEQ ID NO: 1.

11 . The bispecific antibody according to claim 10 wherein said antibody is capable of binding a KPI-3 epitope comprising amino acid residue Ile 211, Lys 213 and/or Arg 215 of SEQ ID NO: 1.

12 . The bispecific antibody according to claim 1 which is a Fab-Fab conjugate or in a full length antibody format.

13 . The bispecific antibody according to claim 1 which is humanized.

14 . The bispecific antibody according to claim 1 which selectively targets TFPIα.

15 . A pharmaceutical composition comprising a first monospecific antibody and a second monospecific antibody, wherein the first monospecific antibody is capable of specifically binding to an epitope within tissue factor pathway inhibitor (TFPI) amino acid residues 1 to 181 of SEQ ID NO: 1;
and the second monospecific antibody is capable of specifically binding to an epitope within TFPI amino acid residues 182 to 276 of SEQ ID NO: 1.

16 . A bispecific antibody or a pharmaceutical composition comprising monospecific antibodies that compete with the multispecific or bispecific antibody or pharmaceutical composition comprising a combination of monospecific antibodies according to claim 1 .

17 . A pharmaceutical composition comprising the bispecific antibody according to claim 1 .

18 - 19 . (canceled)

20 . A method for treating coagulopathy in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition according to claim 15

Assignees

• Novo Nordisk As

Inventors

• Krogh Berit O
• Kofod-Hansen Mikael
• Hilden Ida
• Petersen Helle H
• Petersen Lars C

Classifications

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• C07K16/468

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title